MRK•benzinga•November 15, 2024 at 12:19 PM

Merck Says European Medicines Agency's Committee for Medicinal Products For Human Use Approves KEYTRUDA (pembrolizumab), Anti-PD-1 Therapy, In Combination With Pemetrexed And Platinum Chemotherapy, For Adult Patients With Unresectable Non-epithelioid Mal

No summary available.

Read the full article from the original source for complete details and context.

Article published on November 15, 2024 by benzinga